Abstract: |
PURPOSE: To compare retinal toxicity as measured by electroretinogram, ocular, and patient survival in retinoblastoma treated with intravitreal melphalan at two concentrations (25 vs. 30 μg). METHODS: Single-center, retrospective analysis of retinoblastoma eyes receiving 25-μg or 30-μg intravitreal melphalan from September 2012 to January 2019. Ocular toxicity was measured by electroretinogram of evaluable injections in 449 injections in 136 eyes. A repeated-measures linear mixed model with a random intercept and slope was applied to account for repeated measures for each eye. RESULTS: Average decline in electroretinogram after each additional injection was -4.9 μV (95% confidence interval -6.3 to -3.4); electroretinogram declined by -4.6 μV (95% confidence interval -7.0 to -2.2) after 25-μg injections and -5.2 μV (95% confidence interval -6.6 to -3.8) after 30-μg injections (P = 0.66). Injection at a new clock site hour was associated with a -3.91-μV lower average (95% confidence interval -7.8 to -0.04). CONCLUSION: Electroretinogram-measured toxicity in retinoblastoma eyes treated with intravitreal injections was not found to be different across 25-μg and 30-μg injections. There were no cases of extraocular extension or metastatic deaths in our patient population. |